MESO Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

3 Analyst Rating

Wall Street analysts forecast MESO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MESO is 29.50 USD with a low forecast of 24.00 USD and a high forecast of 35.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

24.00

Averages

29.50

High

35.00

Current: 0.000

Low

24.00

Averages

29.50

High

35.00

Jefferies

Hold

Buy

upgrade

2025-11-25

Reason

Jefferies

Price Target

2025-11-25

upgrade

Hold

Buy

Reason

Jefferies upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3.

Jefferies

David Stanton

Hold

Buy

upgrade

2025-11-25

Reason

Jefferies

David Stanton

Price Target

2025-11-25

upgrade

Hold

Buy

Reason

As previously reported, Jefferies analyst David Stanton upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3. Ryoncil continues to be rolled out and the firm forecasts 78 patients will complete therapy in FY26, up from 63, while updating its estimates for fiscal Q2 results and FY26 forecasts.

Jefferies

David Stanton

Buy

Hold

downgrade

2025-07-18

Reason

Jefferies

David Stanton

Price Target

2025-07-18

downgrade

Buy

Hold

Reason

Jefferies analyst David Stanton downgraded Mesoblast to Hold from Buy with a price target of A$2.60, up from A$2.50, following the fiscal Q4 report. The firm estimates 68 paid infusions were given during the quarter of Ryoncil in the U.S. with six patents likely having completed treatment. Jefferies updated fiscal 2025 estimates and awaits the company's annual results in August.

Piper Sandler

Edward Tenthoff

Buy

Reiterates

$15 → $24

2025-02-07

Reason

Piper Sandler

Edward Tenthoff

Price Target

$15 → $24

2025-02-07

Reiterates

Buy

Reason

Valuation Metrics

The current forward P/E ratio for Mesoblast Ltd (MESO.O) is -194.58, compared to its 5-year average forward P/E of -18.86. For a more detailed relative valuation and DCF analysis to assess Mesoblast Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-18.86

Current PE

-194.58

Overvalued PE

15.49

Undervalued PE

-53.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.76

Current EV/EBITDA

261.47

Overvalued EV/EBITDA

92.76

Undervalued EV/EBITDA

-100.27

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

29.46

Current PS

21.25

Overvalued PS

46.16

Undervalued PS

12.76

Financials

Annual

Quarterly

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MESO News & Events

Events Timeline

No data

News

9.5

01-09NASDAQ.COM

PinnedMesoblast Reports 60% Quarterly Sales Growth for Ryoncil, Shares Jump 8%

9.5

01-09Benzinga

Mesoblast Reports 60% YoY Growth in Ryoncil Sales to $35.1 Million

9.5

01-09Globenewswire

Mesoblast Reports 60% Revenue Growth to $35.1 Million in Q4

People Also Watch

Frequently Asked Questions

What is Mesoblast Ltd (MESO) stock price today?

The current price of MESO is 20.96 USD — it has increased 5.49 % in the last trading day.

What is Mesoblast Ltd (MESO)'s business?

Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

What is the price predicton of MESO Stock?

What is Mesoblast Ltd (MESO)'s revenue for the last quarter?

Mesoblast Ltd revenue for the last quarter amounts to NaN USD, decreased % YoY.

What is Mesoblast Ltd (MESO)'s earnings per share (EPS) for the last quarter?

Mesoblast Ltd. EPS for the last quarter amounts to USD, decreased % YoY.

What changes have occurred in the market's expectations for Mesoblast Ltd (MESO)'s fundamentals?

The market is revising Upward the revenue expectations for Mesoblast Limited (MESO) for FY2026, with the revenue forecasts being adjusted by 20.6% over the past three months. During the same period, the stock price has changed by 15.55%.

How many employees does Mesoblast Ltd (MESO). have?

Mesoblast Ltd (MESO) has 81 emplpoyees as of January 11 2026.

What is Mesoblast Ltd (MESO) market cap?

Today MESO has the market capitalization of 2.70B USD.